IVD Quality Control Market to Reach US$ 2.2 Bn by 2031, Growing at 5.3% CAGR as Labs Shift to Automated QC Workflows: New Report by Wissen Research

Wissen Research projects the global IVD quality control market will grow from USD 1.7 billion in 2026 to USD 2.2 billion by 2031, a 5.3% CAGR. Rising testing volumes, more complex diagnostics, regulatory requirements, automation, and point-of-care expansion are cited as growth drivers; implementation costs and cross-platform standardization remain challenges. North America led the market in 2025, while Asia-Pacific is projected to be the fastest-growing region.

Analysis

This is a category tailwind, not an earnings catalyst: a third-party market forecast does not establish incremental revenue, share gains, or margin contribution for any listed company. The most investable second-order effect is mix shift. As labs centralize monitoring across analyzers and point-of-care sites, control materials may remain necessary, but software, data connectivity, and cross-platform comparison could capture a larger share of incremental value. Bio-Rad’s Unity platform and third-party controls are positioned to benefit if labs prioritize vendor-neutral oversight; Roche’s integrated workflow could instead favor bundled ecosystems. That tension makes platform adoption and customer retention more informative than headline market growth. TMO’s RealBio collaboration may help local execution in China, but the release provides no evidence of orders or economics; treat it as an option, not a forecast revision. Siemens Healthineers’ sustainability credential could help procurement differentiation, but is unlikely on its own to move group earnings near term.

Over days, expect little durable repricing absent company-specific disclosure. Over 1–3 months, watch earnings commentary for QC consumables growth, software attach rates, and APAC demand. Over 6–18 months, automation and decentralized testing could support recurring demand, while implementation costs and heterogeneous platforms slow adoption. Contrarian point: compliance-driven demand is relatively resilient, but QC is only one part of lab quality management and the market’s modest projected growth may not justify a thematic multiple premium. Thesis weakens if vendors report flat QC-related sales, low software adoption, or lab spending deferrals.

Key Decisions for Investors

• Do not trade the market forecast alone; treat the report as a watchlist signal rather than an earnings estimate. The forecast source and company-level exposure need independent verification.
• Prefer monitoring Bio-Rad (BIO) for evidence that Unity and third-party controls are driving cross-platform adoption; verify QC-related sales, recurring revenue, and customer retention before considering a long.
• Track TMO’s China collaboration as an alert, not a buy catalyst. Reassess only with evidence of commercial launches, regulatory progress, or disclosed revenue contribution.
• At the next results cycle, compare QC consumables growth and digital-software attach rates across BIO, ABT, DHR, TMO, QDEL, and SHL. Flat growth or weak adoption despite broader testing demand would falsify the near-term monetization thesis.